Obinutuzumab + Glofitamab + Venetoclax Oral Product + Zanubrutinib Oral Capsule
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle-Cell
Conditions
Lymphoma, Mantle-Cell
Trial Timeline
Feb 21, 2025 → Mar 1, 2032
NCT ID
NCT06558604About Obinutuzumab + Glofitamab + Venetoclax Oral Product + Zanubrutinib Oral Capsule
Obinutuzumab + Glofitamab + Venetoclax Oral Product + Zanubrutinib Oral Capsule is a phase 2 stage product being developed by Roche for Lymphoma, Mantle-Cell. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06558604. Target conditions include Lymphoma, Mantle-Cell.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06558604 | Phase 2 | Recruiting |
Competing Products
20 competing products in Lymphoma, Mantle-Cell